The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany

NCT03205722 · clinicaltrials.gov ↗
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Business objectives have changed

Conditions

Interventions

Sponsor

Bristol-Myers Squibb